Stock NWBO NORTHWEST BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Northwest Biotherapeutics, Inc.

Equities

NWBO

US66737P6007

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:22:39 2024-06-26 EDT 		5-day change 1st Jan Change
0.455 USD +1.36% Intraday chart for Northwest Biotherapeutics, Inc. -0.44% -35.66%
05-10 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-21 Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 107.5 129.2 1,255 663.3 830.1 821.8
Enterprise Value (EV) 1 102.1 146.9 1,265 686.1 849.4 865.3
P/E ratio -1.69 x -5.97 x -2.09 x -11.7 x -7.59 x -11.7 x
Yield - - - - - -
Capitalization / Revenue 261 x 53.6 x 972 x 660 x 493 x 425 x
EV / Revenue 248 x 60.9 x 979 x 683 x 505 x 448 x
EV / EBITDA -2.35 x -5.35 x -22.7 x -13.1 x -12.9 x -16 x
EV / FCF -4.62 x -3.89 x 3.67 x -2.54 x -17.5 x -7.32 x
FCF Yield -21.6% -25.7% 27.2% -39.4% -5.72% -13.7%
Price to Book -2.28 x -3.03 x -3.49 x -5.35 x -6.54 x -12.5 x
Nbr of stocks (in thousands) 523,231 601,330 822,716 947,622 1,058,132 1,172,382
Reference price 2 0.2055 0.2149 1.525 0.7000 0.7845 0.7010
Announcement Date 4/2/19 3/16/20 3/31/21 3/1/22 2/28/23 3/5/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.412 2.41 1.291 1.005 1.683 1.932
EBITDA 1 -43.47 -27.44 -55.72 -52.38 -65.93 -53.98
EBIT 1 -44.76 -27.46 -55.8 -52.7 -67.18 -55.51
Operating Margin -10,863.35% -1,139.54% -4,322.62% -5,243.98% -3,991.74% -2,873.08%
Earnings before Tax (EBT) 1 -35.79 -20.3 -529.8 179.1 -105 -62.6
Net income 1 -35.79 -20.3 -529.8 179.1 -105 -62.6
Net margin -8,687.86% -842.16% -41,039.58% 17,823.48% -6,240.76% -3,240.11%
EPS 2 -0.1217 -0.0360 -0.7307 -0.0598 -0.1034 -0.0600
Free Cash Flow 1 -22.08 -37.73 344.4 -270 -48.55 -118.1
FCF margin -5,360.07% -1,565.55% 26,680.32% -26,865.44% -2,884.89% -6,114.6%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/2/19 3/16/20 3/31/21 3/1/22 2/28/23 3/5/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 17.7 9.87 22.8 19.3 43.4
Net Cash position 1 5.43 - - - - -
Leverage (Debt/EBITDA) - -0.6435 x -0.1772 x -0.4347 x -0.2926 x -0.8046 x
Free Cash Flow 1 -22.1 -37.7 344 -270 -48.6 -118
ROE (net income / shareholders' equity) 75.8% 44.7% 260% -73.6% 91.7% 82.3%
ROA (Net income/ Total Assets) -76% -102% -160% -90.2% -117% -117%
Assets 1 47.07 19.98 330.7 -198.7 89.41 53.4
Book Value Per Share 2 -0.0900 -0.0700 -0.4400 -0.1300 -0.1200 -0.0600
Cash Flow per Share 2 0.0400 0 0.0100 0.0200 0.0100 0
Capex 1 0.19 0.36 6.61 6.02 2.9 3.44
Capex / Sales 46.84% 14.94% 512.01% 598.51% 172.43% 177.9%
Announcement Date 4/2/19 3/16/20 3/31/21 3/1/22 2/28/23 3/5/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NORTHWEST BIOTHERAPEUTICS, INC. Stock Northwest Biotherapeutics, Inc.
-35.66% 552M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.85% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+22.03% 116B
ARGENX SE Stock argenx SE
+22.18% 27.03B
BIONTECH SE Stock BioNTech SE
-21.25% 20.36B
GENMAB A/S Stock Genmab A/S
-16.89% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.31% 15.91B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.75% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.10% 13.59B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NWBO Stock
  4. Financials Northwest Biotherapeutics, Inc.